Method Of Using A Transgenic Nonhuman Animal In An In Vivo Test Method (e.g., Drug Efficacy Tests, Etc.) Patents (Class 800/3)
  • Patent number: 11582957
    Abstract: The invention relates to a genetically modified mouse comprising a heterozygous mutation of Tardbp (TDP-43) gene in that the Asn at amino acid 390 in TDP-43 is substituted with an amino acid that is different from Asn, wherein the genetically modified mouse exhibits Amyotrophic lateral sclerosis (ALS)-like phenotypes, TDP-43 proteinopathies and/or motor neuron degeneration. The invention also so relates to an isolated spinal cord motor neuron differentiated from an embryonic stem cell (ESC) that is obtained from an offspring of a genetically modified mouse according to the invention. Methods for identifying an agent alleviating and/or suppressing ALS-TDP pathogenesis are also disclosed.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 21, 2023
    Assignee: ACADEMIA SINICA
    Inventors: Che-Kun James Shen, Shih-Ling Huang
  • Patent number: 11572401
    Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 7, 2023
    Assignee: Howard Hughes Medical Institute
    Inventors: Douglas Kim, Karel Svoboda, Loren Looger, Eric Schreiter
  • Patent number: 11536713
    Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: December 27, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki
  • Patent number: 11528895
    Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: December 20, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, John McWhirter, Naxin Tu, Vera Voronina, Cagan Gurer, Karolina Meagher, Sean Stevens
  • Patent number: 11497198
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: November 15, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Chaoshe Guo, Rui Huang, Lei Zhao, Yanan Guo, Yang Bai, Meiling Zhang, Jiawei Yao
  • Patent number: 11441125
    Abstract: The present application relates to a method for reestablishing stem cells capable of forming chimeras, and cells obtained by the method. The method of the present invention is a technique for monocloning stem cells, for example, capable of forming chimeras from a heterogeneous cell population to obtain high-quality stem cells.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: September 13, 2022
    Assignee: JICHI MEDICAL UNIVERSITY
    Inventors: Hitoshi Endo, Yasumitsu Nagao, Yutaka Hanazono, Kaoru Tominaga, Tsukasa Ohmori
  • Patent number: 11416776
    Abstract: A system for identifying and enumerating cross-body degradations, the system comprising a computing device, wherein the computing device is configured to receive biological extraction data. Computing device may generate a first body degradation function, using a machine-learning model trained with data that correlates biological extraction data with rates of biological degradation of the body. Computing device may determine, using a machine-learning process and the first body degradation function, a second body degradation function, wherein the second body degradation function describes a rate of biological degradation that is statistically associated with a first body degradation function. Computing device identify, using the first body degradation function and the second body degradation function, a predictive relationship between the first body degradation function and the second body degradation function according to the biological extraction datum.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: August 16, 2022
    Assignee: KPN INNOVATIONS, LLC.
    Inventor: Kenneth Neumann
  • Patent number: 11319557
    Abstract: Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: May 3, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Aris N. Economides, Andrew J. Murphy, Peter Matthew Lengyel, Peter H. A. Yang
  • Patent number: 11284609
    Abstract: A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: March 29, 2022
    Assignee: MarvelBiome, Inc.
    Inventors: Jothi Amaranath Govindan, Elamparithi Jayamani, Priti H. Chatter, Mukesh Chatter
  • Patent number: 11234420
    Abstract: Provided is a method for preparing a PD-1 gene-modified humanized animal model. The method utilizes the CRIPSR/Cas9 technique to replace partial fragments of a mouse PD-1 gene with fragments of a human PD-1 gene using homologous recombination by constructing a targeting vector, thereby preparing a gene-modified humanized mouse. This mouse can normally express a PD-1 protein containing the functional domain of the human PD-1 protein, and can be used as an animal model for mechanism research regarding PD-1, PD-L1 and other signals, for screening regulators, and for toxicological research. The method has an important and high application value in studies on functions of the PD-1 gene and in the development of new drugs.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: February 1, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Xiaofei Zhou, Yuting Hu, Yanan Guo, Jichao Du
  • Patent number: 11175289
    Abstract: A TRPM8 related peptide fragment, comprising amino acid sequence as shown in SEQ ID No: 1-18 is provided. Furthermore, application of TRPM8 protein, TRPM8 related peptide fragment and their antibodies in preparing diagnostic reagent for chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is provided. By detecting level of TRPM8 protein molecule, TRPM8 related peptide fragment and their antibodies, the chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is effectively diagnosed, and the present invention is capable of effectively making a distinction between CP/CPPS and other diseases of prostate.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: November 16, 2021
    Inventors: Lei Han, Xiaohui Zhou, Yuyan Zhou, Li Zhou, Guohua Li, Yongzhen Li
  • Patent number: 11085930
    Abstract: The present disclosure relates to a method of screening an anti-NRP1 antibody or an antigen-binding fragment thereof by use of patient-derived tumor spheroids overexpressing NRP1 and an animal model comprising the same, and more particularly to a method of screening an antibody or an antigen-binding fragment thereof through in vitro and in vivo panning by use of a patient-derived tumor spheroid containing NRP1 and an animal model transplanted with the same, respectively.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: August 10, 2021
    Assignee: AIMED BIO INC.
    Inventors: Do-Hyun Nam, Jae Hyun Lee
  • Patent number: 11058697
    Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: July 13, 2021
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 11013219
    Abstract: The present application provides a novel drug screening platform designed to identify drugs that favorably modulate cellular bioenergetics in the human brain of a zebrafish which has been modified by altering a teleost gene that corresponds to a human gene associated with a brain dysfunction disorder (such as epilepsy). The drug screening platform are also useful for determining a mutation in a human gene associated with a brain dysfunction disorder that is associated with a human individual responsive to the treatment of a compound. Also provided are modified teleosts useful for the methods described herein.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 25, 2021
    Assignee: Path Therapeutics, Inc.
    Inventors: Deborah M. Kurrasch, Jong Rho, Kingsley Ibhazehiebo
  • Patent number: 11013411
    Abstract: Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spa
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: May 25, 2021
    Assignees: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, CORNELL UNIVERSITY
    Inventors: Stephen Macknik, Susana Martinez-Conde, Nozomi Nishimura, Christopher Schaffer, Mitch Pender
  • Patent number: 10974064
    Abstract: The present disclosure provides methods of modulating a feature of a behavioral state. The methods involve inhibiting or activating the activity of a bed nucleus of stria terminalis (BNST) neuron, a BNST subnucleus, or a neuronal output to or from a BNST neuron. Animals encounter environmental conditions that require rapid switching among different behavioral states to increase the likelihood of survival and reproduction.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 13, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Sung-Yon Kim, Avishek Adhikari
  • Patent number: 10918095
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: February 16, 2021
    Assignee: Beijing Biocytogen Co., Ltd
    Inventors: Yuelei Shen, Yang Bai, Jian Ni, Rui Huang, Chengzhang Shang, Yanan Guo
  • Patent number: 10912287
    Abstract: Provided is a method for preparing a PD-1 gene-modified humanized animal model. The method utilizes the CRIPSR/Cas9 technique to replace partial fragments of a mouse PD-1 gene with fragments of a human PD-1 gene using homologous recombination by constructing a targeting vector, thereby preparing a gene-modified humanized mouse. This mouse can normally express a PD-1 protein containing the functional domain of the human PD-1 protein, and can be used as an animal model for mechanism research regarding PD-1, PD-L1 and other signals, for screening regulators, and for toxicological research. The method has an important and high application value in studies on functions of the PD-1 gene and in the development of new drugs.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 9, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Xiaofei Zhou, Yuting Hu, Yanan Guo, Jichao Du
  • Patent number: 10900018
    Abstract: The present invention is in the field of stem cell biology, in particular in the field of developmental and regenerative biology. The invention generally relates to a method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally resembles the terminal ductal-lobular unit. More precisely, said cells are generated by dissociating mammary epithelial tissue, thereby gaining cells and culturing said cells in presence of a compound which elevates cAMP levels in a collagen gel. Under said culturing conditions said cells form a multicellular organoid unit facilitating to obtain a breast stem cell by isolating a single cell from said multicellular organoid unit. The present invention also relates to enriching said cells and differentiating them to a multicellular organoid that morphologically and/or functionally resembles the terminal ductal-lobular unit and use of said cells or said multicellular organoid in testing a compound.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 26, 2021
    Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)
    Inventors: Christina H. Scheel, Jelena R. Linnemann, Lisa K. Meixner, Haruko Miura
  • Patent number: 10899826
    Abstract: The present disclosure provides pharmaceutical compositions including a plurality of IgG2 anti-CGRP antagonist antibodies comprising a high content of particular IgG2 disulfide isomers, and methods of using the same.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: January 26, 2021
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Jason Bock, John Kim
  • Patent number: 10822618
    Abstract: Transgenic non-human animals, e.g., rodents, e.g., mice comprising genomic mutations that inactive all of the serpin1A genes and thus lack any functional serpinA1 genes. As a result of the genomic mutations, the animals express no hepatic or circulatory AAT protein. Also provided herein are cells and tissues derived from the transgenic mice.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: November 3, 2020
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Florie Borel
  • Patent number: 10822604
    Abstract: The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: November 3, 2020
    Assignee: MORPHOSYS AG
    Inventors: Katja Siegers, Jan Van Den Brulle
  • Patent number: 10792311
    Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 6, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yuan Cheng, Aaron J. W. Hsueh, Yorino Sato
  • Patent number: 10765762
    Abstract: Provided herein, inter alia, are non-human animals comprising nucleic acid sequences encoding a C3 protein that comprises a human sequence as well as transgenic non-human animals comprising a C3 gene that is human in whole or in part as well as methods for using the same to screen for candidate therapeutic molecules to treat complement-related nephropathies. Also provided herein are methods for improving kidney function in an individual diagnosed with or thought to have a complement-related nephropathy.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 8, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kishor Devalaraja-Narashimha, Lori Morton, Yifan Luo, Cong Huang, Karolina Meagher, Sarah Casanova
  • Patent number: 10750723
    Abstract: A method of identifying individual zebrafish (Danio rerio), containing the steps of: observing a striped pattern for each of an anal fin and a caudal fin of each individual of two or more zebrafish in side view; determining characteristics of each individual from the observed striped pattern; and identifying each individual on the basis of the characteristics obtained.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 25, 2020
    Assignee: Kao Corporation
    Inventor: Takahiro Hasumura
  • Patent number: 10676518
    Abstract: The ?4?2 neuronal nicotinic acetylcholine receptor (nAChR) plays a crucial role in nicotine addiction. The invention studied the effect of subunit phosphorylation on ?4?2 nAChR function and expression, and eleven residues located in the M3-M4 cytoplasmic loop were mutated to alanine and aspartic acid. When nicotine was used as an agonist, four mutations exhibited a statistically significant hypersensitivity to nicotine (S438D, S469A, Y576A, and S589A). Additionally, two mutations (S516D and T536A) that displayed normal activation with ACh displayed remarkable reductions in sensitivity to nicotine. The invention provides a knock-in mutant construct for the development of a transgenic mouse line with reduced nicotine sensitivity to be used in future studies.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 9, 2020
    Assignee: University of Puerto Rico
    Inventors: Jose A Lasalde-Dominicci, Nilza M Biaggi-Labiosa, Emir Aviles-Pagan, Daniel Caballero-Rivera
  • Patent number: 10613079
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 7, 2020
    Assignee: Q-STATE BIOSCIENCES, INC.
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 10493111
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: December 3, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 10487146
    Abstract: Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: November 26, 2019
    Assignee: The University of Vermont and State Agricultural College
    Inventor: Marilyn J. Cipolla
  • Patent number: 10471107
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 12, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 10426815
    Abstract: Embodiments described herein relates to compositions and methods of preventing and/or treating itch in a subject using a therapeutically effective amount of a MRG receptor antagonist. e.g., a tripeptide QWF. In one embodiment, the itch is a non-histamine mediated itch.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: October 1, 2019
    Assignee: The General Hospital Corporation
    Inventors: Ethan A. Lerner, Ehsan Azimi, Vemuri B. Reddy
  • Patent number: 10377990
    Abstract: The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SIgma-Aldrich Co. LLC
    Inventors: Nan Lin, Joaquina Mascarenhas, Audrey Chang, David Onions, Henry George, Kevin Kayser
  • Patent number: 10345292
    Abstract: The following discloses mammalian cells lines that stably express functional nematode acetylcholine receptor subunits. The resulting expression of functional ion channels has been made possible by the stable co-expression of the chaperone protein, RIC3. These cell lines are extremely useful for the high throughput screening (HTS) of compounds, to identify new candidate parasiticidal, including nematocidal, active ingredients.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 9, 2019
    Assignees: BOEHRINGER INGELHEIM ANIMAL HEALTH INC., SANOFI
    Inventors: Lance Hammerland, Brenda Bondesen, Jean-Marie Chambard, Thierry Vermat, Werner Dittrich, Michel Partiseti, Qing Zhou-Liu, Cathy Cojean, Rachid Boukaiba, Eric Tagat
  • Patent number: 10314295
    Abstract: Provided is a non-human animal that is highly practical as a hyperuricenia model, the non-human animal being the following: (a) a non-human animal obtained by producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction; and subsequently administering a purine base-containing substance to the primary chimeric non-human animal, or (b) a non-human animal obtained by producing a serially transplanted chimeric non-human animal via two steps, a first step being a step of producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction, a second step being a step of transplanting the human hepatocytes grown in the body of the primary chimeric non-human animal to an immunodeficient non-human animal with liver dysfunction, the second step being performed one or more times; and subsequently administering a purine base-containing substance to the seri
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: June 11, 2019
    Assignee: PHOENIXBIO CO., LTD.
    Inventors: Masakazu Kakuni, Yumiko Iwasaki, Chise Mukaidani
  • Patent number: 10266585
    Abstract: Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies and their use in detecting and/or treating traumatic brain injury or chronic traumatic encephalopathy.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: April 23, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERITY OF TEXAS SYSTEM
    Inventor: Rakez Kayed
  • Patent number: 10190136
    Abstract: Transgenic non-human animals, e.g., rodents, e.g., mice comprising genomic mutations that inactive all of the serpin1A genes and thus lack any functional serpinA1 genes. As a result of the genomic mutations, the animals express no hepatic or circulatory AAT protein. Also provided herein are cells and tissues derived from the transgenic mice.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: January 29, 2019
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Florie Borel
  • Patent number: 10155030
    Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: December 18, 2018
    Assignee: University of South Florida
    Inventors: Chuanhai Cao, Xiaoyang Lin
  • Patent number: 10093620
    Abstract: Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 9, 2018
    Assignee: PELLFICURE PHARMACEUTICALS, INC.
    Inventors: Per Borgström, Adrian Chrastina, Veronique Therese Baron, Parisa Abedinpour
  • Patent number: 10023922
    Abstract: In some aspects, described herein is a DNA methylation reporter. In some aspects, the DNA methylation reporter comprises a promoter whose activity can be affected by exogenous methylation changes without being independently regulated by the DNA methylation machinery, operably linked to a DNA sequence that encodes a reporter molecule. In some embodiments the DNA methylation reporter comprises (i) a promoter derived from a mammalian imprinted gene promoter; and (ii) a sequence that encodes a reporter molecule that is detectable in individual mammalian cells, wherein the promoter is operably linked to the sequence that encodes the reporter molecule. Also described are nucleic acids that comprise the DNA methylation reporter, cells that have the DNA methylation reporter integrated into their genome, and non-human mammals comprising cells that have the DNA methylation reporter integrated into their genome.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 17, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Yonatan Stelzer, Rudolf Jaenisch
  • Patent number: 10010565
    Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yuan Cheng, Aaron J. W. Hsueh, Yorino Sato
  • Patent number: 9986721
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: June 5, 2018
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Claude Auriault, Véronique Pancre, Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Patent number: 9945844
    Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: April 17, 2018
    Assignee: Howard Hughes Medical Institute
    Inventors: Loren Looger, Karel Svoboda, Douglas Kim, Rex Kerr
  • Patent number: 9894888
    Abstract: The present invention provides a transgenic mouse which comprises a deficiency for murine T lymphocytes, B lymphocytes and NK cells, a deficiency for murine MHC class I and MHC class II molecules, and a functional xenogenic SIRP? transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines. The said mouse is also useful for testing the in vivo metabolism of xenobiotic compounds.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: February 20, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvie Garcia, Malika Serra-Hassoun
  • Patent number: 9820475
    Abstract: The disclosure relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD 163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 21, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Randall S. Prather, Kevin D. Wells, Kristin M. Whitworth
  • Patent number: 9783801
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: October 10, 2017
    Assignee: BerGenBio ASA
    Inventors: David Micklem, James Lorens
  • Patent number: 9717222
    Abstract: Provided is a gene in drosophila designated as dSLC5A1. This gene is responsible for taste independent nutrient sensing. Activation of neurons expressing this gene results in hunger behavior. Provided are compositions and methods for identifying agents that can interfere with hunger behavior.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 1, 2017
    Assignee: New York University
    Inventors: Greg Seong-Bae Suh, Monica Dus
  • Patent number: 9700024
    Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 11, 2017
    Assignees: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
  • Patent number: 9670264
    Abstract: Described herein are recombinant integral membrane proteins having multiple transmembrane domains that have been engineered to be less hydrophobic, through alteration of the amino acid sequence of the native protein, but retain the ability to bind their natural ligand. The decreased hydrophobicity of the described proteins makes them more water soluble than the native protein, which allows the described proteins to be expressed in bacteria in large quantities and isolated in the absence of membranes, all while retaining the ability to interact with known ligands.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: June 6, 2017
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Renyu Liu, Jeffery G Saven, Jose Manuel Perez-Aguilar, Felipe Matsunaga, Jin Xi
  • Patent number: 9662407
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: May 30, 2017
    Assignee: TRANSLATUM MEDICUS INC.
    Inventor: Shelley Romayne Boyd
  • Patent number: 9639660
    Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: May 2, 2017
    Assignees: REFERNCEBIOLABS, CO., LTD, GENCURIX, INC.
    Inventors: Young Kee Shin, Mi Jeong Kwon, En Sel Oh, Yong Ho In, Sang Seok Koh